摘要
目的研究胰岛素样生长因子Ⅱ(IGF-Ⅱ)及胰岛素样生长因子Ⅰ受体(IGF-ⅠR)的表达与宫颈癌分型、分期、浸润和转移等各种病理学指标之间的相关性,从而评价其与宫颈癌预后的关系。方法对46例宫颈癌、22例转移淋巴结中及12例正常宫颈组织用免疫组化方法检测其IGF-Ⅱ及IGF-ⅠR的表达。结果宫颈癌组织中IGF-Ⅱ蛋白表达率为41.3%(19/46),IGF-Ⅱ在淋巴结转移组明显高于无转移组(χ2=5.5024,P=0.019),IGF-Ⅱ阳性组5年生存率显著低于阴性组(χ2=7.404,P=0.0065)。IGF-ⅠR阳性率45.7%(21/46),IGF-ⅠR在淋巴结转移组明显高于无转移组(χ2=5.4968,P=0.019)。且IGF-Ⅱ和IGF-ⅠR呈正相关关系(r=0.737,P<0.01)。结论宫颈癌广泛存在IGF-Ⅱ和IGF-ⅠR蛋白的过表达,且二者与宫颈癌发生浸润转移相关;联合检测IGF-Ⅱ和IGF-ⅠR蛋白表达有助于宫颈癌的预后判断,并为宫颈癌生物学行为的判断提供新的有意义的指标。
Objective To study the correlation between the expression of insulin-like growth factor-Ⅱ（ IGF-Ⅱ） and insulin-like growth factor-Ⅰ receptor（ IGF-ⅠR） and the histological type,stage,infiltration as well as metastasis of uterine cervical cancer so as to evaluate the relationship between IGF-Ⅱ,IGF-ⅠR expression and cervical cancer prognosis. Methods The expression of IGF-Ⅱ and IGF-ⅠR were tested by S-P immunohistochemistry in 46 cases of cervical cancer and 12 cases of common cervical tissues. Results The positive expression rate of IGF-Ⅱ in cervical cancer group was 41. 3%（ 19 /46）,which was significantly higher in the positive-lymph node metastasis than in the non-lymph node metastasis group（ x^2= 5. 5024,P= 0. 019）. The survival rate were higher for patients in the negative IGF-Ⅱ group than those in the positive group（ x^2= 7. 404,P = 0. 0065）. The positive expression rate of IGF-ⅠR in cervical cancer group was 45. 7%（ 21 /46）,which was significantly higher in the positive-lymph node metastasis than in the non group（ x^2= 5. 4968,P = 0. 019）. And a positive correlation was found between IGF-Ⅱ and IGF-ⅠR expression in tumor（ r = 0. 737,P 〈0. 01）. Conclusion The excessive expression of IGF-Ⅱ and IGF-ⅠR occur frequently in cervical cancers.The expression of IGF-Ⅱ and IGF-ⅠR may be useful markers for assessing invasion,metastasis and prognosis of cervical cancer.
出处
《哈尔滨医科大学学报》
CAS
北大核心
2014年第4期293-296,F0004,共5页
Journal of Harbin Medical University
基金
黑龙江省科技厅基金资助(LC02C17)
关键词
宫颈癌
胰岛素样生长因子Ⅱ
胰岛素样生长因子Ⅰ受体
cervical carcinoma
insulin-like growth factor-Ⅱ
insulin-like growth factor-Ⅰ re-ceptor
